| FUNDAMENTALS |
| MarketCap: |
0.0077 mill
|
| EPS: |
-0.180
|
| P/E: |
0
|
| Earnings Date: |
Aug 08, 2024 |
| SharesOutstanding: |
38.55 mill
|
| Avg Daily Volume: |
0.0074 mill
|
| RATINGS |
| Rating CashFlow: |
Strong Sell
|
|
| Return On Equity: |
Strong Buy
|
|
| Return On Asset: |
Strong Sell
|
|
| DE: |
Strong Sell
|
|
| P/E: |
Sell
|
|
| Price To Book: |
Strong Sell
|
|
| QUARTER GROWTHS |
|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | | | | | | |
| Asset | | | | | | |
| Debt | | | | | | |
| PE RATIO: COMPANY / SECTOR |
|
0.00x
|
|
Company: PE 0 | sector: PE -11.58
|
| PE RATIO: COMPANY / INDUSTRY |
|
N/A
|
|
Company: PE 0 | industry: PE -107.25
|
| DISCOUNTED CASH FLOW VALUE |
|
N/A
|
|
N/A
|
| Expected Trading Range (DAY) |
$ -0.0868 - 0.0872
( +/- 43 500.00%)
|
|
ATR Model: 14 days
|
Insider Trading
| Date |
Person |
Action |
Amount |
type |
| 2022-03-10 | Verstraete George | Buy | 0 | |
| 2021-08-09 | Soave Darlene | Buy | 800 000 | Warrant (Option to buy) |
| 2021-06-30 | Zolty David | Buy | 4 860 | Common Stock |
| 2021-06-30 | Soave Darlene | Buy | 59 507 | Common Stock |
| 2021-06-30 | Brown Dennis M | Buy | 2 976 | Common Stock |
| INSIDER POWER |
|
0.00
|
| Last
47 transactions |
| Buy:
4 869 574 | Sell:
6 627 844 |
Forecast:
16:00 - $0.0002
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
| Indicator Signals |
| RSI 21 |
|
| SMA |
|
| Trend |
|
| Trend 2 |
|
| Trend 3 |
|
| Volume Signals |
| Price |
$0.0002 (0.00% )
|
| Volume |
0.0010 mill
|
| Avg. Vol. |
0.0074 mill
|
| % of Avg. Vol |
13.57 %
|
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CLCS
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other non-malignant organ diseases, and various cancers and non-malignant diseases. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York.
The Technical Analyst
